Segra International Corp. ("Segra") announced a new exclusive global distribution agreement with Grounded Genetics and The Holding Company. Under the terms of the agreements, Segra will partner with both companies to bring a significant collection of proven, award-winning, and unreleased genetics to Canadian and International markets. Access to these genetics will be available in the fall of 2023 in the form of tissue culture mother plants and tissue culture plantlets (clones).
In addition to their extensive collection, Segra will collaborate with both groups to offer custom phenotype selection and breeding projects for customers on an "a la carte" basis. "We believe that pheno selection and breeding initiatives are better suited in a dedicated environment vs. the grow rooms of our customers. Offering this service fills a gap in the marketplace and allows our customers to focus on what they do best cultivation," said Matthew Don-Carolis, Vice President of Sales for Segra.
"I am thrilled to announce our partnership with Grounded Genetics and The Holding Company. Their global reputation and experience in breeding and genetic selection is impressive. Their ability and commitment to identify the best cultivars for specific environments and outcomes aligns perfectly with our mission to deliver exceptional products to our customers," said Jamie Blundell, CEO of Segra. "Together, we can leverage our collective strengths to refine the cannabis experience and provide unmatched quality and variety in the market. This partnership marks a significant milestone for our companies, and I am excited to embark on this journey of discovery and growth."
Ramone, CEO of Grounded Genetics, commented, "We are excited to announce our partnership with Segra International. We have been waiting for the right partner, and Segra has demonstrated that they are a global leader in both cannabis tissue culture and molecular biology IP, with an unparalleled global distribution network. As a breeder, getting our genetics to market in a clean, safe format is critical to the long-term success of our business and mitigates the risk and spread of disease, a significant issue facing the industry."
"In addition to the business rationale, Segra is a great fit culturally, where we are all focused on doing the right thing for our partners and customers alike," said Dave, CEO of The Holding Company. "This collaboration represents an incredible opportunity to leverage the synergies between our companies and drive innovation in the cannabis industry. Segra's DNA fingerprinting technology also brings confidence that our genetics will be preserved safely in tissue culture and adds a level of protection that our genetics will not be widely distributed."
This partnership presents an opportunity to leverage years of innovation and genetic development for growers to introduce true-to-type, proven, and diverse cultivars into their respective markets. Through Segra's clean stock tissue culture plantlets, growers can have peace of mind, knowing that the plants they receive are free from detectable pests, pathogens, viruses, or viroids.
For more information:
Segra International Corp.